• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Acutus Medical Inc.

    1/21/25 4:14:09 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AFIB alert in real time by email
    POS AM 1 dp223620_posam-268730.htm FORM POS AM

     

    As filed with the Securities and Exchange Commission on January 21, 2025.

     

    Registration Statement No. 333-266804

    Registration Statement No. 333-268730

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1
    TO
    Form S-3 Registration Statement No. 333-266804

    Form S-3 Registration Statement No. 333-268730

     

    UNDER
    THE SECURITIES ACT OF 1933

     

     

     

    Acutus Medical, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   45-1306615
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

     

    2210 Faraday Ave., Suite 100 

    Carlsbad, CA 92008
    (442) 232-6080

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

    Takeo Mukai

    Chief Executive Officer & Chief Financial Officer

    Acutus Medical, Inc.

    2210 Faraday Ave., Suite 100

    Carlsbad, CA 92008

    (442) 232-6080

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies of all communications, including all communications sent to the agent for service, should be sent to:

    Alan F. Denenberg

    Jason Bassetti
    Davis Polk & Wardwell LLP
    900 Middlefield Road Suite 200
    Redwood City, CA 94063
    (650) 752-2000

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statements.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒    

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    EXPLANATORY NOTE – DEREGISTRATION OF SECURITIES

     

    Acutus Medical, Inc., a Delaware corporation (the “Company”), is filing these post-effective amendments (the “Post-Effective Amendments”) to the following Registration Statements on Form S-3 (each, a “Registration Statement,” and collectively, the “Registration Statements”), which have been previously filed with the Securities and Exchange Commission (the “SEC”), to deregister any and all shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:

     

    ·Registration Statement on Form S-3 (No. 333-266804), filed with the SEC on August 11, 2022 and declared effective on August 19, 2022, registering up to 16,537,961 shares of Common Stock, which consists of (i) an aggregate of 5,296,772 shares of Common Stock acquired by the selling stockholders identified therein from the Company in private placements or in transactions registered with the SEC, in privately negotiated secondary transactions or in open market transactions; (ii) an aggregate of 346,689 shares of Common Stock underlying warrants that the Company issued to the selling stockholders identified therein in a private placement at an exercise price of $0.10 per share under the terms of the warrant dated as of June 7, 2018; (iii) an aggregate of 419,991 shares of Common Stock underlying warrants that the Company issued to the selling stockholders identified therein in a private placement at an exercise price of $16.67 per share under the terms of the warrant dated as of May 20, 2019; (iv) an aggregate of 6,665,841 shares of Common Stock issuable upon conversion of the Company’s Series A Common Stock Equivalent Convertible Preferred Stock, par value $0.001, that the Company issued to the selling stockholders identified therein pursuant to certain exchange agreements entered into on August 23, 2021; (v) an aggregate of 3,779,018 shares of Common Stock underlying warrants that the Company issued to certain of the selling stockholders identified therein in a private placement at an exercise price of $1.11 per share pursuant to a warrant purchase agreement dated June 30, 2022; (vi) an aggregate of 18,606 shares of Common Stock and shares underlying options held by a member of our board of directors and a partner in Deerfield Management Company, L.P. (“Deerfield Management”), for the benefit and at the direction of Deerfield Management; and (vii) an aggregate of 11,044 shares of Common Stock and shares underlying options held by a member of our board of directors and a member of OrbiMed Advisors LLC (“OrbiMed Advisors”), for the benefit and at the direction of OrbiMed Advisors and its affiliates.

     

    ·Registration Statement on Form S-3 (No. 333-268730), filed with the SEC on December 9, 2022 and declared effective on December 21, 2022, registering up to an aggregate offering amount of $15,000,000 of shares of Common Stock.

     

    On January 21, 2025, the Company announced its intention to apply for the voluntary deregistration of its Common Stock from the reporting requirements under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) with the SEC. In connection with the Company’s voluntary decision to deregister, the Company has terminated any and all offerings pursuant to its existing registration statements, including the Registration Statements. Accordingly, this filing is made pursuant to an undertaking made by the Company in Part II of each Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of each offering. The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all securities registered but unsold or otherwise unissued under the Registration Statements as of the date hereof.

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California, on this 21st day of January, 2025.

     

      ACUTUS MEDICAL, INC.
       
       
      By: /s/ Takeo Mukai
        Name: Takeo Mukai
        Title: Chief Executive Officer & Chief Financial Officer

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Takeo Mukai his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to the Registration Statements and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, these Post-Effective Amendments have been signed below by the following persons on behalf of the Registrant in the capacities and on the date indicated.

     

    Name   Title   Date
             
    /s/ Takeo Mukai   Chief Executive Officer & Chief Financial Officer   January 21, 2025
    Takeo Mukai   (Principle Executive Officer & Principal Financial and Accounting Officer)    
             
    /s/ Shaden Marzouk   Chair of the Board   January 21, 2025
    Shaden Marzouk, M.D.        
             
    /s/ Andrew ElBardissi   Director   January 21, 2025
    Andrew ElBardissi, M.D.        
             
    /s/ Jason Garland   Director   January 21, 2025
    Jason Garland        
             
    /s/ David Bonita   Director   January 21, 2025
    David Bonita, M.D.        
             
    /s/ Niamh Pellegrini   Director   January 21, 2025
    Niamh Pellegrini        
             
    /s/ John Sheridan   Director   January 21, 2025
    John Sheridan        
             

     

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB

    DatePrice TargetRatingAnalyst
    1/20/2022Buy → Neutral
    BTIG
    1/14/2022$10.00 → $3.00Buy → Hold
    Canaccord Genuity
    11/15/2021Neutral → Underweight
    JP Morgan
    11/12/2021Neutral → Underweight
    JP Morgan
    11/12/2021$18.00 → $10.00Buy
    Canaccord Genuity
    10/22/2021$10.00Neutral
    Goldman
    7/15/2021$11.00 → $18.00Hold → Buy
    Canaccord Genuity
    More analyst ratings

    $AFIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acutus Medical Reports Full Year 2024 Financial Results

    CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024. Full Year 2024 Financial ResultsRevenue from Continuing Operations was $20.2 million for 2024, an increas

    3/24/25 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Announces Operational Downsizing

    CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, "Following an extensive strategic review by the Company's Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products." Takeo Mukai, CEO & CFO of Acutus, added, "The operational downsizing impacts our team, and it is difficult to part with our valued and highly talented colleag

    12/4/24 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

    CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024. Thi

    11/14/24 4:26:42 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director by deputization Flynn James E

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    1/28/25 9:00:08 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Mukai Takeo covered exercise/tax liability with 8,475 units of Form 4, decreasing direct ownership by 10% to 72,874 units (SEC Form 4)

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    3/4/24 5:20:05 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sohn Tom covered exercise/tax liability with 7,582 units of Form 4, decreasing direct ownership by 7% to 105,009 units (SEC Form 4)

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    2/7/24 4:12:59 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Acutus Medical downgraded by BTIG

    BTIG downgraded Acutus Medical from Buy to Neutral

    1/20/22 9:29:42 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Acutus Medical from Buy to Hold and set a new price target of $3.00 from $10.00 previously

    1/14/22 8:31:41 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical downgraded by JP Morgan

    JP Morgan downgraded Acutus Medical from Neutral to Underweight

    11/15/21 7:17:46 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    SEC Filings

    View All

    SEC Form 10-K filed by Acutus Medical Inc.

    10-K - Acutus Medical, Inc. (0001522860) (Filer)

    3/24/25 5:27:27 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Acutus Medical, Inc. (0001522860) (Filer)

    3/24/25 4:07:31 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.

    SCHEDULE 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    1/28/25 5:40:03 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Leadership Updates

    Live Leadership Updates

    View All

    Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer

    CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer. Preliminary Unaudited Fourth Quarter and Full Year 2022 ResultsThe Company expects fourth quarter 2022 revenue of approximately $4.7-$4.9 million compared to $4.4 million in the fourth quarter of 2021. Year-over-year growth was driven by an increase in commercial AcQMap pr

    1/9/23 6:00:00 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

    SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

    9/7/22 8:30:00 AM ET
    $AFIB
    $AVGR
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Acutus Medical Appoints Niamh Pellegrini to Board of Directors

    CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021. Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. "Niamh is an experienced and proven executive and commercial leader," said Vince Burgess, President and CEO of Acutu

    8/12/21 4:02:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Financials

    Live finance-specific insights

    View All

    Acutus Medical to Cancel Third Quarter 2023 Conference Call

    CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus

    11/10/23 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical to Announce Third Quarter 2023 Financial Results

    CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a

    11/2/23 4:13:07 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Reports Second Quarter 2023 Financial Results

    CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital salesQuarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabil

    8/7/23 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acutus Medical Inc.

    SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)

    11/14/24 1:03:20 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Acutus Medical Inc.

    SC 13G - Acutus Medical, Inc. (0001522860) (Subject)

    5/17/24 5:20:26 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care